The Effect of Oral Carnosine Supplementation on Urinary TGF-beta in Diabetic Nephropathy: A Randomized Controlled Trial
- Conditions
- Diabetic nephropathy with aged over 18 yrsCarnosine, diabetic nephropathy, transforming growth factor beta
- Registration Number
- TCTR20200724002
- Lead Sponsor
- /A
- Brief Summary
rinary TGF-beta significantly decreased with carnosine supplement (-17.8% of the baseline values), whereas it tended to increase with placebo (+16.9% of the baseline values) (between-group difference. Whereas, blood urea nitrogen, serum creatinine, glomerular filtration rate and other biochemical parameters did not change during the study period including urinary albuminuria. The both groups were well tolerated with no serious side-effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
The inclusion criteria were T2DM, age of 18 years old or older, urine albumin-creatinine ratio (UACR) of 30-299 mg/g creatinine at least 2 in 3 within 3 to 6 months, stable dose of ACEI or ARB for blood pressure control at least 3 months before enrolling, and stable hemoglobinA1C (HbA1C) within 3 months prior to the study.
The exclusion criteria were active infections, chronic kidney disease from non-diabetic cause, advanced malignancy, history of hypersensitivity to protein nutrients, problems with nutrients absorption of gastrointestinal tract and liver disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome was the decrease in the level of urinary levels of TGF-β at 12 weeks after start of the intervention solid-phase specific sandwich enzyme-linked immunosorbent assay (ELISA)
- Secondary Outcome Measures
Name Time Method secondary outcome was the decrease in the level of urine albumin/creatinine ratio at 12 weeks after start of the intervention immunonephelometric assay